Status:
COMPLETED
Investigation of Mass Balance of the Test Drug and Major Metabolites
Lead Sponsor:
Bayer
Conditions:
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to: a) Determine how the body takes up the test drug and distributes it into various body organs and tissues, how it processes the drug and how it ultimately removes it; a...
Detailed Description
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.
Eligibility Criteria
Inclusion
- Male ≥ 18 years; female ≥ 50 years without childbearing potential (confirmed by either: age ≥ 60; or history of hysterectomy; or hormone analysis in serum: Estradiol ≤ 20 pg/mL and follicle stimulating hormone ≥ 40 IU/L)
- Solid tumor
- Adequate function of major organs
- Failed previous cancer treatment
- Peripheral venous access
Exclusion
- Concurrent severe and/or uncontrolled disease
- Brain tumors
- Marked constipation
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2007
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT00432302
Start Date
January 1 2007
End Date
November 1 2007
Last Update
December 14 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Liège, Belgium, 4000